Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
Researchers used a large prospective online survey to test whether psychedelic drug use changes people’s metaphysical beliefs. After psychedelic use, people tended to move away from physicalist or materialist views and toward panpsychism and fatalism. Except for fatalism, these shifts lasted for at least 6 months. The shifts were linked…
This study used a smartphone app to compare 4,050 people who said they microdose psychedelics with 4,653 people who did not. Psilocybin was the most common microdose substance, and people who microdosed often said they did so for health and wellness reasons. In people who reported past mental health concerns,…
Researchers followed 953 people who microdosed psilocybin and 180 non-microdosing controls for about 30 days. Microdosers showed small-to-medium improvements in mood and overall mental health at one month compared with controls. These improvements were seen across genders, age groups, and in people with and without prior mental health concerns. The…
This small, exploratory study gave people with moderate to severe major depressive disorder placebo first (19 people) and then a single dose of psilocybin (0.3 mg/kg) to 15 people four weeks later, with all dosing embedded in therapy based on Acceptance and Commitment Therapy (ACT). After the psilocybin session, measures…
Researchers ran an online survey of about 174 people who had used psychoactive drugs to see how these drugs affected obsessive–compulsive disorder (OCD) symptoms. Participants reported that classic psychedelics were the only drugs that helped reduce OCD symptoms, and bigger immediate effects (which were linked to higher doses) were tied…
